Suboptimal medication adherence in Parkinson's disease
Identifieur interne : 003718 ( Main/Curation ); précédent : 003717; suivant : 003719Suboptimal medication adherence in Parkinson's disease
Auteurs : Katherine A. Grosset [Royaume-Uni] ; Ian Bone [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-11.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Age Factors, Aged, Antiparkinson Agents (therapeutic use), Chemotherapy, Drug Administration Schedule, Drug Monitoring (methods), Drug Prescriptions, Female, Humans, Male, Middle Aged, Nervous system diseases, Observation, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Patient Compliance (statistics & numerical data), Quality of life, Self Administration, quality of life, suboptimal medication use.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinson Disease.
- methods : Drug Monitoring.
- psychology : Parkinson Disease.
- statistics & numerical data : Patient Compliance.
- Age Factors, Aged, Drug Administration Schedule, Drug Prescriptions, Female, Humans, Male, Middle Aged, Observation, Self Administration.
Abstract
Patients take less medication than prescribed in many disease areas but evidence for suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single‐center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Switzerland) over 3 months. Of 68 patients approached, 6 declined and 8 dropped out, leaving 54 patients (taking 117 preparations) with available data. Poorer compliance was associated significantly with younger age, with taking more antiparkinsonian tablets per day, with higher depression scores, and with poorer quality of life. Of the 54 evaluable patients, 11 (20%) had average total compliance of under 80% (underusers) and 43 (80%) had average total compliance of over 80% (satisfactory adherence). Underusers had median total compliance of 65% (interquartile range, 37–74) versus 98% (interquartile range, 93–102) in the satisfactory adherence group. Timing compliance (number of doses taken in the correct time interval) was poor in both underusers (median, 11%; interquartile range, 2–20) and those with satisfactory adherence (median, 25%; interquartile range, 11–73). In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one‐fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20602
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001250
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001250
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002124
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F63
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002F63
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002F50
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001349
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001349
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001349
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004E01
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D01
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001020
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001D03
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005181
Links to Exploration step
ISTEX:258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Suboptimal medication adherence in Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
</author>
<author><name sortKey="Bone, Ian" sort="Bone, Ian" uniqKey="Bone I" first="Ian" last="Bone">Ian Bone</name>
</author>
<author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20602</idno>
<idno type="url">https://api.istex.fr/document/258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001250</idno>
<idno type="wicri:Area/Istex/Curation">001250</idno>
<idno type="wicri:Area/Istex/Checkpoint">002124</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:suboptimal:medication:adherence</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16037924</idno>
<idno type="wicri:Area/PubMed/Corpus">002F63</idno>
<idno type="wicri:Area/PubMed/Curation">002F63</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F50</idno>
<idno type="wicri:Area/Ncbi/Merge">001349</idno>
<idno type="wicri:Area/Ncbi/Curation">001349</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001349</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:suboptimal:medication:adherence</idno>
<idno type="wicri:Area/Main/Merge">004E01</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0077745</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D01</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001020</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D03</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:suboptimal:medication:adherence</idno>
<idno type="wicri:Area/Main/Merge">005181</idno>
<idno type="wicri:Area/Main/Curation">003718</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Suboptimal medication adherence in Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bone, Ian" sort="Bone, Ian" uniqKey="Bone I" first="Ian" last="Bone">Ian Bone</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-11">2005-11</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1502">1502</biblScope>
<biblScope unit="page" to="1507">1507</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20</idno>
<idno type="DOI">10.1002/mds.20602</idno>
<idno type="ArticleID">MDS20602</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Drug Administration Schedule</term>
<term>Drug Monitoring (methods)</term>
<term>Drug Prescriptions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Observation</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Patient Compliance (statistics & numerical data)</term>
<term>Quality of life</term>
<term>Self Administration</term>
<term>quality of life</term>
<term>suboptimal medication use</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Compliance</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Drug Administration Schedule</term>
<term>Drug Prescriptions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Observation</term>
<term>Self Administration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term>
<term>Parkinson maladie</term>
<term>Qualité vie</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients take less medication than prescribed in many disease areas but evidence for suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single‐center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Switzerland) over 3 months. Of 68 patients approached, 6 declined and 8 dropped out, leaving 54 patients (taking 117 preparations) with available data. Poorer compliance was associated significantly with younger age, with taking more antiparkinsonian tablets per day, with higher depression scores, and with poorer quality of life. Of the 54 evaluable patients, 11 (20%) had average total compliance of under 80% (underusers) and 43 (80%) had average total compliance of over 80% (satisfactory adherence). Underusers had median total compliance of 65% (interquartile range, 37–74) versus 98% (interquartile range, 93–102) in the satisfactory adherence group. Timing compliance (number of doses taken in the correct time interval) was poor in both underusers (median, 11%; interquartile range, 2–20) and those with satisfactory adherence (median, 25%; interquartile range, 11–73). In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one‐fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2005:Grosset K:suboptimal:medication:adherence"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Suboptimal medication adherence in Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bone, Ian" sort="Bone, Ian" uniqKey="Bone I" first="Ian" last="Bone">Ian Bone</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0077745</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0077745 INIST</idno>
<idno type="RBID">Pascal:06-0077745</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D01</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001020</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D03</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:suboptimal:medication:adherence</idno>
<idno type="wicri:Area/Main/Merge">005181</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Suboptimal medication adherence in Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bone, Ian" sort="Bone, Ian" uniqKey="Bone I" first="Ian" last="Bone">Ian Bone</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences, Southern General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Quality of life</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Chimiothérapie</term>
<term>Qualité vie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients take less medication than prescribed in many disease areas but evidence for suhoptimal therapy adherence in Parkinson's disease (PD) is limited. A single-center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Switzerland) over 3 months. Of 68 patients approached, 6 declined and 8 dropped out, leaving 54 patients (taking 117 preparations) with available data. Poorer compliance was associated significantly with younger age, with taking more antiparkinsonian tablets per day, with higher depression scores, and with poorer quality of life. Of the 54 evaluable patients, 11 (20%) had average total compliance of under 80% (underusers) and 43 (80%) had average total compliance of over 80% (satisfactory adherence). Underusers had median total compliance of 65% (interquartile range, 37-74) versus 98% (interquartile range, 93-102) in the satisfactory adherence group. Timing compliance (number of doses taken in the correct time interval) was poor in both underusers (median, 11%; interquartile range, 2-20) and those with satisfactory adherence (median, 25%; interquartile range, 11-73). In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one-fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Suboptimal medication adherence in Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
</author>
<author><name sortKey="Bone, Ian" sort="Bone, Ian" uniqKey="Bone I" first="Ian" last="Bone">Ian Bone</name>
</author>
<author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20602</idno>
<idno type="url">https://api.istex.fr/document/258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001250</idno>
<idno type="wicri:Area/Istex/Curation">001250</idno>
<idno type="wicri:Area/Istex/Checkpoint">002124</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:suboptimal:medication:adherence</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16037924</idno>
<idno type="wicri:Area/PubMed/Corpus">002F63</idno>
<idno type="wicri:Area/PubMed/Curation">002F63</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F50</idno>
<idno type="wicri:Area/Ncbi/Merge">001349</idno>
<idno type="wicri:Area/Ncbi/Curation">001349</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001349</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:suboptimal:medication:adherence</idno>
<idno type="wicri:Area/Main/Merge">004E01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Suboptimal medication adherence in Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A." last="Grosset">Katherine A. Grosset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bone, Ian" sort="Bone, Ian" uniqKey="Bone I" first="Ian" last="Bone">Ian Bone</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-11">2005-11</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1502">1502</biblScope>
<biblScope unit="page" to="1507">1507</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20</idno>
<idno type="DOI">10.1002/mds.20602</idno>
<idno type="ArticleID">MDS20602</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Drug Administration Schedule</term>
<term>Drug Monitoring (methods)</term>
<term>Drug Prescriptions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Observation</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson's disease</term>
<term>Patient Compliance (statistics & numerical data)</term>
<term>Self Administration</term>
<term>quality of life</term>
<term>suboptimal medication use</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Compliance</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Drug Administration Schedule</term>
<term>Drug Prescriptions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Observation</term>
<term>Self Administration</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients take less medication than prescribed in many disease areas but evidence for suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single‐center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Switzerland) over 3 months. Of 68 patients approached, 6 declined and 8 dropped out, leaving 54 patients (taking 117 preparations) with available data. Poorer compliance was associated significantly with younger age, with taking more antiparkinsonian tablets per day, with higher depression scores, and with poorer quality of life. Of the 54 evaluable patients, 11 (20%) had average total compliance of under 80% (underusers) and 43 (80%) had average total compliance of over 80% (satisfactory adherence). Underusers had median total compliance of 65% (interquartile range, 37–74) versus 98% (interquartile range, 93–102) in the satisfactory adherence group. Timing compliance (number of doses taken in the correct time interval) was poor in both underusers (median, 11%; interquartile range, 2–20) and those with satisfactory adherence (median, 25%; interquartile range, 11–73). In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one‐fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD. © 2005 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003718 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003718 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:258F446A8E6F25A8B4B1AD8D47DD7DB8EC6E2A20 |texte= Suboptimal medication adherence in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |